- Home
- LUCD vs LENZ Comparison
LUCD vs LENZ Comparison
Compare LUCD & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | LENZ |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.4M | 155.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LUCD | LENZ |
|---|---|---|
| Price | $0.96 | $5.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.13 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 1.5M | 910.5K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,346,000.00 | ★ $19,088,000.00 |
| Revenue This Year | $115.58 | $50.42 |
| Revenue Next Year | $130.54 | $197.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.86 | $4.68 |
| 52 Week High | $1.63 | $50.19 |
Technical Indicators
Market Signals| Indicator | LUCD | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 46.17 |
| Support Level | $0.88 | $5.23 |
| Resistance Level | $1.11 | $6.18 |
| Average True Range (ATR) | 0.05 | 0.37 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 58.89 | 34.11 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.